Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABFRA:8LY -4.98%26 PB Ratio is 305.50 as of Jul. 27, 2026, which is 3630% above its 10-year median of 8.19. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,230 Biotechnology companies, OncoZenge AB ranks worse than 99.67% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-27), OncoZenge AB's share price is €0.611. OncoZenge AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.00. Hence, OncoZenge AB's PB Ratio of today is 305.50.
Warning Sign:
OncoZenge AB stock PB Ratio (=274.4) is close to 2-year high of 274.4.
The historical rank and industry rank for OncoZenge AB's PB Ratio or its related term are showing as below:
FRA:8LY'
s PB Ratio Range Over the Past 10 Years
Min: 4.92 Med: 8.19 Max: 274.4
Current: 274.4
During the past 6 years, OncoZenge AB's highest PB Ratio was 274.40. The lowest was 4.92. And the median was 8.19.
FRA:8LY's PB Ratio is ranked worse than 99.67% of 1230
companies
in the Biotechnology industry
Industry Median: 2.785
vs FRA:8LY: 274.40
During the past 12 months, OncoZenge AB's average Book Value Per Share Growth Rate was -97.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -36.40% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of OncoZenge AB was -26.60% per year. The lowest was -50.20% per year. And the median was -38.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
OncoZenge AB PB Ratio Related Terms
OncoZenge AB PB Ratio Historical Data
* Premium members only.
The historical data trend for OncoZenge AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OncoZenge AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
OncoZenge AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
OncoZenge AB (FRA:8LY) has a PB Ratio of 305.50 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OncoZenge AB and its competitors. This is 3630% above median its historical median of 8.19. Over the past decade, OncoZenge AB's PB Ratio has ranged from 4.92 to 274.40. According to the industry distribution chart, OncoZenge AB ranks #1226 out of 1230 companies in the Biotechnology industry, placing it in the top 99.7%.
Is OncoZenge AB's PB Ratio too high?
OncoZenge AB's current PB Ratio of 305.50 is 3630% above median its 10-year median of 8.19. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 274.40. The Biotechnology industry median PB Ratio is 2.79. OncoZenge AB's value of 305.50 is 10869.5% above this industry median. Based on the distribution chart, OncoZenge AB ranks #1226 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #1226 out of 1230 companies for PB Ratio. This places OncoZenge AB in the lower half of its industry. The industry median PB Ratio is 2.79. OncoZenge AB's value of 305.50 is 10869.5% above this benchmark. Historically, OncoZenge AB's own PB Ratio has ranged from 4.92 to 274.40 over the past decade. While the company's 10-year median is 8.19 vs. the industry median of 2.79, OncoZenge AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoZenge AB's current PB Ratio of 305.50 is 10869.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OncoZenge AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoZenge AB's current PB Ratio is 305.50, which is 3630% above median its own 10-year median of 8.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current PB Ratio of 305.50. The current PB Ratio is 305.50, which is 3630% above median its 10-year median of 8.19 and 10869.5% above the Biotechnology industry median of 2.79. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current PB Ratio is 305.50 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score
Get the complete analysis for FRA:8LY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8LY has been successfully added to your 
